首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 蛋白質療法的投藥技術
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

蛋白質療法的投藥技術

Delivery Technologies for Protein Therapeutics: Assessment and Outlook

出版商 Insight Pharma Reports
出版日期 2007年03月 商品編碼 50067
內容資訊 英文 185 pages
價格
US $ 1498 PDF by E-mail ( Single User License)
US $ 1875 PDF by E-mail (Single Site License)


蛋白質療法的投藥技術 是由出版商Insight Pharma Reports在2007年03月所出版的。 這份英文市場調查報告書包含185 pages 價格從美金1498起跳。

簡介

因基因領域調查工作獲得全球高度評價的美國市調公司 Insight Pharma Reports (總公司:麻薩諸塞州),針對蛋白質療法的投藥技術進行詳細的調查分析,並出版調查報告書 "Delivery Technologies for Protein Therapeutics: Assessment and Outlook" 。

本報告書內容包括:蛋白質療法的投藥技術動向、口服、經皮膚投藥技術的趨勢、蛋白質工程技術概要等。內容綱要摘記如下:

第1章 介紹:蛋白質療法的投藥技術趨勢

  • 為什麼需要更好的蛋白質療法的投藥方式呢?
    • 替代注射的方法
  • 本報告書的架構
  • 蛋白質工程技術
  • 非注射技術
  • 胰島素
  • 商業及市場發展預測
    • 非注射技術的競爭
  • 技術趨勢什麼時候才會互相融合?

第2章 延長半衰期的治療用蛋白質工程

  • 介紹
  • 利用PEGylation延長半衰期
  • 利用特定用途的PEGylation延長半衰期
  • 利用與聚唾液酸的結合延長半衰期
  • 利用清蛋白基因融合延長半衰期
  • 利用與清蛋白結合延長半衰期
  • 利用與清蛋白結合的脂肪酸延長半衰期
  • 利用與清蛋白結合的縮氨酸延長半衰期
  • 利用與連球菌清蛋白結合的範圍延長半衰期
  • 利用運鐵蛋白基因的融合延長半衰期
  • 利用高血糖化延長半衰期
  • 利用糖甘化完成及GlycoPEGylation延長半衰期
  • 利用人類化糖甘化延長半衰期
  • 利用蛋白酶抗體突變延長半衰期

第3章 提昇投藥品質的其他蛋白質工程技術

  • 利用生物資訊學降低免疫原性
  • 利用生物資訊學使蛋白質聚集
  • 利用高壓技術使蛋白質聚集摺疊

第4章 經皮膚投藥技術

  • 介紹
  • 利用微頻電極陣列的投藥
  • 利用超音波的主動投藥
  • 利用超音波的被動投藥
  • 利用熱燒的投藥
  • 利用離子電導入法投藥
  • 利用傳遞體(Transfersomes)的投藥

第5章 口服投藥技術

  • 介紹
  • 利用傳遞體分子的口服投藥
  • 利用結晶化技術的口服投藥
  • 利用磷酸鈣奈米粒子的口服投藥
  • 利用口腔噴劑的口服投藥
  • 利用兩性寡合體的口服投藥

第6章 蛋白質經肺及經鼻投藥技術

  • 利用乾粉吸入器對肺的投藥
  • 其他蛋白質吸入技術
    • 醫療實驗中的產品競爭
  • 利用融合抗體轉介運輸穿胞的蛋白質對肺的投藥
  • 利用黏膜吸收促進劑的經鼻投藥:第1部
  • 利用黏膜吸收促進劑的經鼻投藥:第2部
  • 利用緊密結合度調節的經鼻投藥

第7章 專家訪談

附錄

企業索引

參考資訊

目錄

Abstract

Some of biotech' s most celebrated successes include:

  • clotting factors
  • anticoagulants
  • modern insulins
  • growth hormone
  • follicle-stimulating hormone
  • hematopoietic growth factors
  • interferons
  • interleukins

What do they have in common? They are therapeutic proteins, a market segment that had $34 billion in sales in 2004 and will have a projected $52.2 billion in sales in 2010*. As patents on first-generation proteins wind down, their owners naturally seek to protect their markets against interlopers. And in current and future battles for market share, protein delivery technologies are major weapons of offense and defense. It is a safe bet that if a therapeutic protein is bringing in big money and its patent is nearing expiration, someone somewhere with a clever technology is planning a market invasion based on improving how the protein is delivered. Delivery Technologies for Therapeutic Proteins: Assessment and Outlook analyzes and assesses protein delivery technologies developed by companies that are targeting:

  • improved insulin delivery
  • improved erythropoietin delivery
  • improved interferon delivery
  • improved growth hormone delivery

The report also analyzes and assesses noninjection delivery technologies, including technologies for:

  • transdermal protein delivery
  • oral protein delivery
  • pulmonary protein delivery
  • nasal protein delivery

Delivery Technologies for Therapeutic Proteins: Assessment and Outlook provides a thorough analysis and assessment of technologies for protein half-life extension and technologies for delivery of protein therapeutics.

Table of Contents

EXECUTIVE SUMMARY

Chapter 1 INTRODUCTION: TRENDS IN TECHNOLOGY FOR DELIVERING PROTEIN THERAPEUTICS

  • 1.1. Why Better Delivery For Therapeutic Proteins Is Needed
    • Alternatives to Injection
  • 1.2. Organization of this Report
  • 1.3. Protein Engineering Technologies
  • 1.4. Non-Injection Technologies
  • 1.5. Insulin: El Dorado of Protein Delivery Tech
    • Multiple Products, Multiple Mechanisms
  • 1.6. Business and Market Outlook
    • Competition Among Noninjection Technologies
  • 1.7. When Will Tech Trends Merge?

Chapter 2 ENGINEERING THERAPEUTIC PROTEINS FOR LONGER HALF-LIFE

  • 2.1. Introduction
    • PEGylated Interferons
  • 2.2. Increasing Half-life by PEGylation
    • Releasable PEGylation
  • 2.3. Increasing Half-life by Site-specific PEGylation
    • ReCODE Technology
  • 2.4. Increasing Half-life by Conjugation with Polysialic Acid
    • PolyXen Technology
  • 2.5. Increasing Half-life by Albumin Gene Fusion
  • 2.6. Increasing Half-life by Albumin Conjugation
    • DAC and PC-DAC Technologies
  • 2.7. Increasing Half-life by Albumin-binding Fatty Acids
  • 2.8. Increasing Half-life by Albumin-binding Peptides
  • 2.9. Increasing Half-life with the Streptococcal Albumin-binding Domain
  • 2.10. Increasing Half-life by Transferrin Gene Fusion
  • 2.11. Increasing Half-life by Hyperglycosylation
  • 2.12. Increasing Half-life by Glycosylation Completion and GlycoPEGylation
  • 2.13. Increasing Half-life by Humanized Glycosylation
  • 2.14. Increasing Half-life by Protease-resistant Point Mutations

Chapter 3 OTHER PROTEIN ENGINEERING TECHNOLOGIES TO IMPROVE PROTEIN DELIVERY

  • 3.1. Reducing Immunogenicity through Bioinformatics
    • Epibase Software
  • 3.2. Reducing Protein Aggregation through Bioinformatics
    • AggreSolve Algorithms
  • 3.3. Refolding Protein Aggregates through High Pressure Technology
    • PreEMT Technology

Chapter 4 TECHNOLOGIES FOR TRANSDERMAL DELIVERY OF PROTEINS

  • 4.1. Introduction
  • 4.2. Delivery by Radio Frequency (RF) Microelectrode Array
  • 4.3. Active Delivery by Ultrasound
    • U-Strip Ultrasound Module
  • 4.4. Passive Delivery by Ultrasound
    • SonoPrep Device
  • 4.5. Delivery by Thermal Burst
    • PassPort System
  • 4.6. Delivery by Iontophoresis
    • Actyve Patches
  • 4.7. Delivery by Transfersomes

Chapter 5 Technologies for Oral Delivery of Proteins

  • 5.1. Introduction
  • 5.2. Oral Protein Delivery using Carrier Molecules
    • Eligen Technology
  • 5.3. Oral Protein Delivery using Crystallization Technology
    • Crystalomics
  • 5.4. Oral Protein Delivery by Calcium Phosphate Nanoparticles
    • BioOral System
  • 5.5. Oral Protein Delivery by Buccal Mouth Spray
    • RapidMist and Oral-lyn
  • 5.6. Oral Protein Delivery using Amphiphilic Oligomers
    • HIM2 to IN-105

Chapter 6 TECHNOLOGIES FOR PULMONARY AND NASAL DELIVERY OF PROTEINS

  • 6.1. Pulmonary Delivery using Dry Powder Inhalers
    • Milestone: Exubera
  • 6.2. Other Protein Inhaler Technologies
    • Competing Products in Clinical Trials
  • 6.3. Pulmonary Delivery using Antibody Transcytosis Fusion Proteins
    • FcRn Pathway
  • 6.4. Nasal Delivery using Mucosal Absorption Enhancers, Part 1
    • IntraVail Technology
    • Pro Tek Excipients
  • 6.5. Nasal Delivery using Mucosal Absorption Enhancers, Part 2
  • 6.6. Nasal Delivery via Tight Junction Modulation

Chapter 7 EXPERT INTERVIEWS

  • 7.1. Abe S. Abuchowski, PhD, CEO, Prolong Pharmaceuticals
  • 7.2. Ajay K. Banga, PhD, Professor and Chair, Department of Pharmaceutical Sciences, Mercer University
  • 7.3. Eric Tomlinson, DSc, PhD, President and CEO, Altea Therapeutics
  • 7.4. Manuel Vega, PhD, CEO Nautilus Biotech

APPENDIX: CHI ADVANCES REPORTS - PROTEIN DRUG DELIVERY SURVEY - DECEMBER 2006

COMPANY INDEX WITH WEB ADDRESSES

REFERENCES

Back to Top